Indefinite Ban on Puberty Blockers for Under-18s Confirmed

Health Secretary Wes Streeting has announced that the prohibition on administering puberty blockers to individuals under 18 years old who are questioning their gender identity will become permanent. Speaking to Members of Parliament, Mr. Streeting stated his intention to make the temporary prohibition, initially implemented in May, indefinite throughout the United Kingdom. This decision follows a consultation process and recommendations from the Commission on Human Medicines. He characterized the prior application of these medications as a “scandal.” The aforementioned expert body, the Commission on Human Medicines, concluded that the prescription of these drugs to children for gender dysphoria constituted an “unacceptable safety risk.” The announcement has elicited responses from campaigners representing opposing viewpoints. Those who advocate for the ban have praised Mr. Streeting’s “integrity,” while those who oppose it have labeled the measure as “discrimination.” Puberty blockers are pharmaceutical agents designed to postpone or halt the onset of puberty. The previous Conservative government initially imposed a temporary ban, which Mr. Streeting subsequently extended on two occasions. On Monday, Mr. Streeting indicated that the review process uncovered instances where children received this treatment after completing an online form and participating in only a single online consultation with a healthcare professional. The Health Secretary emphasized the government’s imperative to base its healthcare decisions on evidence. This directive comes after the release of a significant review earlier in the current year, conducted by paediatrician Dr. Hilary Cass, which examined gender care services for children. The review highlighted an absence of robust evidence concerning the efficacy of puberty-blocking drugs for individuals under the age of 18. In March, NHS England determined that puberty blockers would cease to be a standard treatment for children diagnosed with gender dysphoria. Subsequently, in May, the Conservative government implemented stricter regulations regarding these medications, instituting an emergency prohibition on their prescription by private and European healthcare providers. This measure was maintained by the Labour government upon their assumption of power during the summer months and was later contested in the High Court, a case which the government ultimately won. During his announcement of the indefinite ban, Mr. Streeting stated: “It is a scandal that medicine was given to vulnerable children without the proof that it was safe or effective.” However, he also confirmed that the planned clinical trial by NHS England, investigating the use of puberty blockers, would proceed as scheduled. He further indicated that the ban is slated for review in 2027, contingent upon the emergence of any new evidence. Individuals under the age of 18 who were already receiving these medications prior to the ban’s implementation have been granted permission to continue their treatment. Helen Joyce, representing the Sex Matters campaign group, commented: “Wes Streeting has shown integrity and bravery in replacing a temporary ban with an indefinite order. “It marks another step towards puberty blockers being relegated to a shameful chapter of history, in which parents and health professionals were emotionally blackmailed into harming children in the name of ‘progress’.” Conversely, Keyne Walker of TransActual stated that the prohibition conveyed an impression of “discrimination plain and simple.” Walker added: “Evidence of the harm of the temporary ban continues to emerge, and will grow now that it has been made permanent.”